Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 13

Trial Status

Terminated2
Other1

Role Distribution

Other Roles3

Activity Timeline

Clinical Trials (3)

NCT04965753Phase 1Terminated
FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
Advanced Synovial Sarcoma
StudydirectorStart date: 2021-08-17
NCT04891757Phase 1Active Not Recruiting
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
Advanced Hematologic MalignancyRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic Leukemia+4 more
StudydirectorStart date: 2021-06-14
NCT04879017Phase 1Terminated
FHD-286 in Subjects With Metastatic Uveal Melanoma
Metastatic Uveal Melanoma
StudydirectorStart date: 2021-05-11

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Abhishek Maiti, MBBS

M.D. Anderson Cancer Center

Related
3 trials

Shared therapeutic areas:

Refractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic Leukemia
Similarity Score7%

Naval G Daver, MD

M.D. Anderson Cancer Center

Related
3 trials

Shared therapeutic areas:

Refractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic Leukemia
Similarity Score7%

Tapan M Kadia

M.D. Anderson Cancer Center

Related
13 trials

Shared therapeutic areas:

Refractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic Leukemia
Similarity Score7%

Filippo Milano

Fred Hutch/University of Washington Cancer Consortium

Related
6 trials

Shared therapeutic areas:

Refractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic Leukemia
Similarity Score7%

Amir Fathi, MD

Massachusetts General Hospital

Related
8 trials

Shared therapeutic areas:

Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
Similarity Score7%

Hiroto Inaba, MD, PhD

St. Jude Children's Research Hospital

Related
5 trials

Shared therapeutic areas:

Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
Similarity Score7%

Nicholas Short

M.D. Anderson Cancer Center

Related
4 trials

Shared therapeutic areas:

Refractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic Leukemia
Similarity Score7%

Amanda Cashen, M.D.

Washington University School of Medicine

Related
8 trials

Shared therapeutic areas:

Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
Similarity Score7%

Farhad Ravandi-Kashani

M.D. Anderson Cancer Center

Related
7 trials

Shared therapeutic areas:

Refractory Acute Myeloid Leukemia
Similarity Score3%

Ryotaro Nakamura

City of Hope Medical Center

Related
10 trials

Shared therapeutic areas:

Refractory Acute Myeloid Leukemia
Similarity Score3%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT04965753Phase 1StudyDirector

FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors

Advanced Synovial Sarcoma
Terminated
NCT04891757Phase 1StudyDirector

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Advanced Hematologic MalignancyRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic Leukemia+4 more
Active Not Recruiting
NCT04879017Phase 1StudyDirector

FHD-286 in Subjects With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma
Terminated

All 3 trials loaded